The Life Sciences sector includes companies involved in biopharmaceuticals, medical manufacturing and distribution, and bio products.
InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
InMed is utilizing its proprietary bioinformatics assessment tool to identify cannabinoid compounds, or combinations thereof, that have therapeutic potential in diseases with high unmet medical needs. The goal is to identify new drug candidates that optimize therapeutic benefit while limiting adverse effects.
InMed’s proprietary in silico drug/disease bioinformatics assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.
International Cannabrands Inc. (formerly GEA Technologies Ltd.), licenses the JuJu Royal Ultra Premium Cannabis brand to producers and processors to develop branded strains of cannabis, infused and edible cannabis consumables, as well as ancillary products such as clothing, paraphernalia, posters, and other products. JuJu Royal is a brand created for and inspired by Julian Marley, Reggae Musician and son of the World Renowned Bob Marley. The brand leverages the natural connection between the artist, Julian Marley, reggae music, and cannabis which the Company believes will allow it to capture a significant share of the branded cannabis market.
The total outstanding does not include 1,570,422 of the 1,836,628 Preferred Shares issued that are convertible into 157,042,200 Common Shares, as these Preferred Shares are held by U.S. residents and there are restrictions on the ability to convert depending upon the percentage held by U.S. residents.
The holders of Preferred Shares are entitled to receive notice of and to attend and vote at all meetings of the shareholders of Common Shares and each Preferred shareholders shall have the right to one vote for each Common Share into which such Preferred Share could then be converted (one hundred (100) Common Shares) in person or by proxy at all meetings of the shareholders of the Company. Please see Section 10 Description of the Securities in the Form 2A Listing Statement.
Lexington Biosciences, Inc. is a development stage medical device company operating within the healthcare industry. Lexington is focused on development and commercialization of non-invasive cardiovascular health monitoring products to allow predictive diagnosis of future cardiovascular events. The current focus of the company is to develop and market the HeartSentry endothelial function measurement product.
Liberty Health Sciences Inc. is an investor and operator in the medical cannabis market, capitalizing on new and existing opportunities in the United States.
Liberty Leaf Holdings Ltd. is a new, Canadian-based, public company whose objective is to be at the forefront of the medicinal and recreational cannabis industry...accelerating revenue-generating businesses within this dynamic and fast-growing sector.
Lifestyle Delivery Systems Inc.’s filmstrip technologies produce an oral delivery system that can be used for energy elixirs, herbal remedies and a smokeless alternative option to medical and recreational users of cannabis. The Company’s technology produces infused strips (similar to breath strips) that are not only a safer, healthier option to smoking but also a new way to accurately meter the dosage and assure the purity of the product. The Company will license the technology to licensees, who will in turn manufacture the strips where the legal use of marijuana is allowed.
Luminor Medical Technologies operates through its two wholly owned subsidiaries - Scout Assessment Corp. and Jamaica BLU Limited. Scout Assessment Corp.’s key product is the Scout DS®, a device that has been regulatory cleared in certain markets both as a non-invasive clinical tool to assist in the identification of both prediabetes and type 2 diabetes. Jamaica BLU Limited holds the exclusive Canadian licence of all current and future cannabis commercial products developed by Rise Research Inc. Currently, Rise Research’s portfolio consists of cannabis-based formulations which support patients with low libido called Jamaica blū and Jamaica pnk.
Marapharm pursues commercial ventures in the medical and approved use categories in the marijuana space in the United States and Canada. In addition, the company has developed an all natural hemp oil product line for the health and wellness sector of it's operations. Marapharm owns property in Las Vegas NV and plans to develop industrial space for close to 300,000' of marijuana cultivation. Marapharm has a 30,000' building in WA for marijuana cultivation.